Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients

Drugs

Volumn 72, Issue 6, 2012, Pages 803-823

  Jonkers, Daisy ^a   Penders, John ^a   Masclee, Ad ^a   Pierik, Marieke ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Balsalazide; Budesonide; Corticosteroids; Inflammatory bowel diseases; Lactobacillus johnsonii; Lactobacillus rhamnosus; Mesalazine; Methotrexate; Probiotics; Tumour necrosis factor alpha inhibitors; VSL 3

Indexed keywords

BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; BACTERIAL STRAIN; BIFIDOBACTERIUM; COMMENSAL; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; HUMAN; ILEOANAL ANASTOMOSIS; INTESTINE FLORA; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS; LIVER ABSCESS; MEDLINE; META ANALYSIS; MUCOSA INFLAMMATION; NONHUMAN; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SACCHAROMYCES BOULARDII; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

ESCHERICHIA COLI NISSLE 1917; LACTOBACILLUS; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS;

EID: 84859918761     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11632710-000000000-00000     Document Type: Review

References (139)

1. Zoetendal EG, Akkermans ADL, Akkermans-van Vliet WM, et al. The host genotype affects the bacterial community in the human gastrointestinal tract. Microb Ecol Health Dis 2001; 13: 129-34 (Pubitemid 32905860)
2. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005 Jun 10; 308 (5728): 1635-8 (Pubitemid 40807514)
3. Frank DN, St Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007 Aug 21; 104 (34): 13780-5 (Pubitemid 350003397)
4. Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008 Jul; 298 (5-6): 463-72 (Pubitemid 351734793)
5. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010 Mar 4; 464 (7285): 59-65
6. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011 May 12; 473 (7346): 174-80
7. Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 2005 Jun; 24 (3): 339-52 (Pubitemid 40668419)
8. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008 Jan 15; 27 (2): 104-19 (Pubitemid 350256609)
9. Quigley EM. Gut microbiota and the role of probiotics in therapy. Curr Opin Pharmacol 2011 Oct 11; 11 (6): 593-603
10. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010 Sep; 44 Suppl. 1: S16-8
11. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011 Apr; 106 Suppl. 1: S2-25; quiz S6
12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 May 31; 411 (6837): 599-603 (Pubitemid 32531408)
13. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011 May; 140 (6): 1704-12
14. Thia KT, Loftus Jr EV, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008 Dec; 103 (12): 3167-82
15. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 2007 Nov 14; 13 (42): 5581-93 (Pubitemid 350031478)
16. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999 May; 116 (5): 1246-9 (Pubitemid 29203034)
17. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122 (1): 44-54 (Pubitemid 34049193)
18. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999; 117 (5): 1089-97 (Pubitemid 29512667)
19. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998 Feb; 114 (2): 262-7 (Pubitemid 28093532)
20. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998 Feb; 4 (1): 29-39 (Pubitemid 128699834)
21. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991 Sep 28; 338 (8770): 771-4
22. Wellmann W, Fink PC, Benner F, et al. Endotoxaemia in active Crohn's disease: treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986 Jul; 27 (7): 814-20 (Pubitemid 16058501)
23. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011 Apr; 106 (4): 661-73
24. Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001; (234): 29-40 (Pubitemid 33070909)
25. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. Isme J 2008 Jul; 2 (7): 716-27 (Pubitemid 351951567)
26. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006 Feb; 55 (2): 205-11 (Pubitemid 43117279)
27. Martinez C, Antolin M, Santos J, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008 Mar; 103 (3): 643-8 (Pubitemid 351405965)
28. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006 Feb; 12 (2): 106-11
29. Swidsinski A, Loening-Baucke V, Vaneechoutte M, et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008 Feb; 14 (2): 147-61 (Pubitemid 351288036)
30. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011 Jan; 17 (1): 179-84
31. Ott SJ, Musfeldt M, Timmis KN, et al. In vitro alterations of intestinal bacterial microbiota in fecal samples during storage. Diagn Microbiol Infect Dis 2004 Dec; 50 (4): 237-45 (Pubitemid 39593146)
32. Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002 Sep; 37 (9): 1034-41
33. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005 Jul; 43 (7): 3380-9 (Pubitemid 40981351)
34. Rehman A, Lepage P, Nolte A, et al. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol 2010 Sep; 59 (Pt 9): 1114-22
35. Walker AW, Sanderson JD, Churcher C, et al. Highthroughput clone library analysis of the mucosaassociated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011 Jan 10; 11: 7
36. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009 Aug; 15 (8): 1183-9
37. Gueimonde M, Ouwehand A, Huhtinen H, et al. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007 Aug 7; 13 (29): 3985-9 (Pubitemid 47272497)
38. Macfarlane S, Furrie E, Kennedy A, et al. Mucosal bacteria in ulcerative colitis. Br J Nutr 2005 Apr; 93 Suppl. 1: S67-72 (Pubitemid 43073410)
39. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005 May; 11 (5): 481-7 (Pubitemid 40704083)
40. Thomazini CM, Samegima DA, Rodrigues MA, et al. High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases. Int J Med Microbiol 2011 Aug; 301 (6): 475-9
41. Vernia P, Gnaedinger A, Hauck W, et al. Organic anions and the diarrhea of inflammatory bowel disease. Dig Dis Sci 1988 Nov; 33 (11): 1353-8 (Pubitemid 19011525)
42. Sepehri S, Kotlowski R, Bernstein CN, et al. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007 Jun; 13 (6): 675-83 (Pubitemid 46909981)
43. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010 Dec; 139 (6): 1844-54.e1
44. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011 May; 140 (6): 1729-37
45. Danese S. Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2011 May; 300 (5): G716-22
46. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med 2009; 60: 97-110
47. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006 Mar; 5 (3): 197-209 (Pubitemid 43336033)
48. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010 Sep; 16 (9): 1583-97
49. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005 Aug; 54 (8): 1182-93 (Pubitemid 41025918)
50. Roda G, Sartini A, Zambon E, et al. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol 2010 Sep 14; 16 (34): 4264-71
51. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011 May 27; 145 (5): 745-57
52. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut 2011 Feb 7; 60 (12): 1739-53
53. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 Nov; 53 (11): 1658-64 (Pubitemid 39434112)
54. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005 Dec 13; 102 (50): 18129-34 (Pubitemid 41798513)
55. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010 Feb; 4 (1): 28-62
56. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011 Dec; 106 (12): 2146-53
57. Kelsen J, Dige A, Schwindt H, et al. Infliximab induces clonal expansion of gammadelta-T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One 2011 Mar 31; 6 (3): e17890
58. Food and Agriculture Organization of the United Nations, WHO. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba: 2001 Oct [online]. Available from URL: http://www.who.int/foodsafety/ publications/fs-management/en/probiotics.pdf [Accessed 2012 Apr 2]
59. Timmerman HM, Koning CJ, Mulder L, et al. Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. Int J Food Microbiol 2004 Nov 15; 96 (3): 219-33 (Pubitemid 39349161)
60. Lebeer S, Vanderleyden J, De Keersmaecker SC. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 2008 Dec; 72 (4): 728-64
61. Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009 Feb-Mar; 24 (1): 10-4
62. Oelschlaeger TA. Mechanisms of probiotic actions: a review. Int J Med Microbiol 2010 Jan; 300 (1): 57-62
63. Borchers AT, Selmi C, Meyers FJ, et al. Probiotics and immunity. J Gastroenterol 2009; 44 (1): 26-46
64. Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007 Jan; 292 (1): G315-22
65. Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010 Jun; 298 (6): G851-9
66. Mattar AF, Teitelbaum DH, Drongowski RA, et al. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002 Oct; 18 (7): 586-90 (Pubitemid 36069911)
67. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007; 2 (12): e1308
68. Claes IJ, De Keersmaecker SC, Vanderleyden J, et al. Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol Nutr Food Res 2011 Oct; 55 (10): 1441-53
69. Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc) 2005 Jul; 41 (7): 453-9 (Pubitemid 41447453)
70. Lorea Baroja M, Kirjavainen PV, Hekmat S, et al. Antiinflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007 Sep; 149 (3): 470-9 (Pubitemid 47256152)
71. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003 Jun; 15 (6): 697-8 (Pubitemid 36688235)
72. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J AmColl Nutr 2003 Feb; 22 (1): 56-63 (Pubitemid 36164458)
73. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteriafermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004 Nov 15; 20 (10): 1133-41 (Pubitemid 39657947)
74. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004 Nov; 10 (11): PI126-31 (Pubitemid 39546045)
75. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005 Jul; 100 (7): 1539-46 (Pubitemid 41032360)
76. Tsuda Y, Yoshimatsu Y, Aoki H, et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007 Nov; 42 (11): 1306-11 (Pubitemid 47537077)
77. Soo I, Madsen KL, Tejpar Q, et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol 2008 Mar; 22 (3): 237-42 (Pubitemid 351676383)
78. Takeda Y, Nakase H, Namba K, et al. Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis. Inflamm Bowel Dis 2009 Nov; 15 (11): 1617-8
79. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009 Nov; 7 (11): 1202-9, 9 e1
80. Matthes H, Krummenerl T, Giensch M, et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010 Apr 15; 10: 13
81. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebocontrolled study. Am J Gastroenterol 2010 Oct; 105 (10): 2218-27
82. Nagasaki A, Takahashi H, Iinuma M, et al. Ulcerative colitis with multidrug-resistant Pseudomonas aeruginosa infection successfully treated with bifidobacterium. Digestion 2010; 81 (3): 204-5
83. D'Inca R, Barollo M, Scarpa M, et al. Rectal administration of Lactobacillus caseiDG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 2011 Apr; 56 (4): 1178-87
84. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997 Oct; 11 (5): 853-8
85. Rembacken BJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354 (9179): 635-9 (Pubitemid 29391428)
86. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13 (8): 1103-8 (Pubitemid 29374113)
87. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004 May 15; 10 (10): 1521-5
88. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 Nov; 53 (11): 1617-23 (Pubitemid 39434105)
89. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006 Jun 1; 23 (11): 1567-74 (Pubitemid 43727463)
90. Guslandi M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol 2010 May-Jun; 44 (5): 385
91. Wildt S, Nordgaard I, Hansen U, et al. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011 Apr; 5 (2): 115-21
92. Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001 Nov; 96 (11): 3218-9 (Pubitemid 33095379)
93. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007 Dec; 50 (12): 2075-82; discussion 82-4 (Pubitemid 350275869)
94. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 Aug; 119 (2): 305-9 (Pubitemid 30621980)
95. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003 Feb 15; 17 (4): 509-15 (Pubitemid 36384810)
96. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003 May; 124 (5): 1202-9 (Pubitemid 36531796)
97. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003 Apr; 38 (4): 409-14 (Pubitemid 36606311)
98. Laake KO, Line PD, Grzyb K, et al. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol 2004 Dec; 39 (12): 1228-35 (Pubitemid 39656838)
99. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004 Jan; 53 (1): 108-14 (Pubitemid 38083018)
100. Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004 Jun; 47 (6): 876-84 (Pubitemid 38702609)
101. Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005 Jan; 40 (1): 43-51
102. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005 Oct 15; 22 (8): 721-8 (Pubitemid 41475334)
103. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008 May; 14 (5): 662-8 (Pubitemid 351742983)
104. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25 (4): 653-8 (Pubitemid 28051605)
105. Mattila-Sandholm T, Blum S, Collins JK, et al. Probiotics: towards demonstrating efficacy. Trends Food Sci Technol 1999; 10: 393-9
106. Doman DB, Goldberg HJ, Golding MI. "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. Am J Gastroenterol 2008 Jan; 103 (1): 251-2
107. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000 Jul; 45 (7): 1462-4 (Pubitemid 30636526)
108. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51 (3): 405-9
109. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006 Jun; 55 (6): 842-7 (Pubitemid 43764556)
110. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004 Mar 15; 4: 5
111. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007 Feb; 13 (2): 135-42 (Pubitemid 46806221)
112. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006 Jun; 11 (2): 193-206 (Pubitemid 44001277)
113. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989 Jan 21; 1 (8630): 164 (Pubitemid 19034066)
114. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003 Jul; 37 (1): 42-7 (Pubitemid 36734332)
115. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4): CD005573
116. Uronis JM, Arthur JC, Keku T, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 2011 Jan; 17 (1): 289-97
117. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005 Mar 15; 174 (6): 3237-46 (Pubitemid 40354026)
118. Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci 2009 May; 1165: 183-9
119. Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 2006 Jul; 74 (7): 4075-82 (Pubitemid 43993340)
120. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004 Mar; 11 (2): 372-8 (Pubitemid 38380820)
121. Claes IJ, Lebeer S, Shen C, et al. Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol 2010 Nov; 162 (2): 306-14
122. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996 Feb; 38 (2): 234-9 (Pubitemid 26046819)
123. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107 (6): 1856-60
124. Landy J, Al-Hassi HO, McLaughlin SD, et al. Etiology of pouchitis. Inflamm Bowel Dis. Epub 2011 Oct 21
125. Navaneethan U, Shen B. Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol 2010 Jan; 105 (1): 51-64
126. Shebani KO, Stucchi AF, McClung JP, et al. Role of stasis and oxidative stress in ileal pouch inflammation. J Surg Res 2000 May 1; 90 (1): 67-75 (Pubitemid 30317179)
127. Kü hbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006 Jun; 55 (6): 833-41 (Pubitemid 43764555)
128. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001 Sep; 96 (9): 2691-9
129. Lammers KM, Vergopoulos A, Babel N, et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis 2005 May; 11 (5): 447-54 (Pubitemid 40704079)
130. Mattila-Sandholm T. The probdemo project: demonstration of the nutritional functionality of probiotic foods. Trends Food Sci Technol 1999; 10 (12): 385-6
131. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43 (7): 842-8 (Pubitemid 351918523)
132. Joossens S, Suenaert P, Noman M, et al. Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. Inflamm Bowel Dis 2005 Sep; 11 (9): 863-4 (Pubitemid 41368279)
133. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998 Feb 17; 39 (3): 237-8 (Pubitemid 28132640)
134. Havenaar R, Ten Brink B, Huis in't Veld JHJ. Selection of strains for probiotic use. In: Fuller R, editor. Probiotics: the scientific basis. London: Chapman & Hall, 1992: 209-24
135. Adams MR. Safety of industrial lactic acid bacteria. J Biotechnol 1999; 68 (2-3): 171-8 (Pubitemid 29090359)
136. Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008 Apr; 66 (4): 192-202
137. Cukovic-Cavka S, Likic R, Francetic I, et al. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 2006; 73 (2-3): 107-10 (Pubitemid 44155911)
138. Farina C, Arosio M, Mangia M, et al. Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 2001 Sep; 33 (3): 251-2 (Pubitemid 32762901)
139. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008 Feb 23; 371 (9613): 651-9